DGK-alpha helps cancer cells gain traction and mobilize

January 23, 2012
A new study in the Journal of Cell Biology reveals how a lipid-converting enzyme helps cancer cells gain traction and mobilize. In this image, Rab-coupling protein (green) gathers at the tip of the pseudopod of an invasive tumor cell. Credit: Elena Rainero

Metastasizing cancer cells often express integrins that provide better traction. A new study in The Journal of Cell Biology reveals how a lipid-converting enzyme helps the cells mobilize these integrins.

Adhesive integrin proteins continually cycle to and from the cell surface. cells that carry mutant forms of the often bias the process, increasing the recycling of a particular integrin that offers a better grip on the fibronectin fibers found in tumors. To make this change, mutant p53 requires the Rab-coupling protein (RCP), which connects the integrins to the Rab GTPases that promote membrane recycling. In turn, RCP links up with a lipid called phosphatidic acid.

A team of researchers led by Jim Norman found that diacylglycerol kinase alpha (DGK-alpha), an enzyme that makes phosphatidic acid, helps cancer cells to get moving. Tumor cells that were short on DGK-alpha didn't recycle the integrin and didn't penetrate into slabs of extracellular matrix.

In metastasizing tumor cells, vesicles sporting RCP are tethered to the tips of the advancing pseudopods. Few of these vesicles built up if DGK-alpha was absent, however, indicating that vesicle tethering requires phosphatidic acid. The researchers found that the particular tumor cells they studied didn't boost levels of DGK-alpha in order to metastasize. Instead, the team thinks that DGK-alpha permits to move following the acquisition of . By manufacturing lipid that binds to RCP, DGK-alpha enables the tumor cells to tether vesicles containing the integrins close to the plasma membrane, where the integrins can readily recycle.

More information: Rainero, E., et al. 2012. J. Cell Biol. doi: 10.1083/jcb.201109112

Related Stories

Recommended for you

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.